We have used a murine Achilles tendinopathy model to investigate whether tissue changes (such as collagen disorganization, chondroid metaplasia, and loss of tensile properties) which are broadly characteristic of human tendinopathies, are accompanied by changes in the expression of chromatin-modifying enzymes and the methylation status of promoter regions of tendon cell DNA. Tendinopathy was induced by two intra-tendinous TGF-b1 injections followed by cage activity or treadmill running for up to 28 days. Activation of DNA methyltransferases occurred at 3 days after the TGF-b1 injections and also at 14 days, but only with treadmill activity. Genome-wide Methyl Mini-Seq TM analysis identified 19 genes with differentially methylated promoters, five of which perform functions with an apparent direct relevance to tendinopathy (Leprel2, Foxf1, Mmp25, Igfbp6, and Peg12). The functions of the genes identified included collagen fiber assembly and pericellular interactions, therefore their perturbation could play a role in the characteristic disorganization of fibers in affected tendons. We postulate that a study of the functional genomics of these genes in animal and human tendon could further delineate the pathogenesis of this multi-factorial complex disease. 
Tendon overuse, due to work and sports-related activities, is the initiating factor for tendinopathy in the majority of patients. 1 Subsequent long-term impaired function due the chronicity of the disease can be dependent on age, genetic predisposition, co-morbidities, 2 and adverse drug effects. 3 A consistent feature of human and animal models of tendinopathy is the appearance of cell clusters in a chondroid matrix as defined by Alcian Blue or SafraninO positive staining. [4] [5] [6] [7] [8] The accumulated sulfated glycosaminoglycans (largely aggrecan chondroitin sulfate) are correlated in humans to advanced clinical symptoms of pain, tenderness, and mechanical dysfunction. 9 Our work on the pathogenic role of such chondroid deposits in murine Achilles tendinopathy showed that a single injection of transforming growth factor-b1 (TGF-b1) into the midportion of the tendon in adult male C57/Bl6 mice resulted in tendon swelling, hyperplastic aggrecan-rich deposits, collagen disorganization, and a loss of tensile properties. Mechanical stimulation of the impaired tendon via treadmill running was accompanied by elimination of chondroid deposits and recovery of mechanical properties. 10 While this model appears very useful for studies on acute tendinopathy, it does not provide an opportunity to examine the pathways associated with chronic disease.
The pathway to chronicity favored by many in the field is that intra-tendinous stressors (metabolic or biomechanical) persist following an initiating injury, such as acute overload, and maintain the cellular activities responsible for chondroid deposition, collagen disorganization, and a loss of tissue material properties. 11, 12 For example, overload of bovine flexor tendon generates areas of rounded cells, largely in the interfascicular matrix, accompanied by collagen disorganization and increased cellular staining for IL6 and MMP13. 13 As commonly seen in other connective tissues, such as cartilage 14 or skin, 15 repair deficiencies in tendinopathy also appear to be associated with chronic turnover of pericellular components without a concomitant increase in the production of stable, longlived matrix structures.
The cellular basis for repair of connective tissues includes proliferation and differentiation of endogenous multipotent cells 16 and in this regard it has been suggested, among many other approaches, that connective tissue growth factor stimulated recruitment of endogenous tendon CD146þ cells may be an effective first step. 17 However, much as for any human complex disease, an understanding of the genomic and epigenomic regulation of the transcriptome will ultimately be needed to delineate the complex interplay between multipotent cells, matrix structure, and biomechanical factors. In relation to tendon biology, expression of G9a, a methyltransferase with specific affinity to the ninth lysine residue of histone three, was shown to regulate cellular differentiation in mouse tenocytes by expression of tenogenic transcription factors, 18 including Scleraxis and Mohawk, which have been heavily studied as necessary modulators for proper tendon development. 19 Additionally, the use of fluoroquinolones (linked to tendinopathy in human patients 20 ) in human embryonic kidney cell cultures resulted in the inhibition of DNA methylases, collagen prolyl 4-hydroxylases, and hypoxia inducible factor 1a (also linked to tendinopathy 21 ), suggesting a mechanistic epigenetic link to chronic tendinopathy. 22 While these recent studies suggest the important role of epigenetics in tendon biology, to our knowledge there are no published studies on analyses for altered DNA methylation and histone modification in human tendinopathies or animal models of the disease. The current study was carried out, using a murine model of Achilles tendinopathy, to identify changes in expression of epigenetic modification enzymes, and to subsequently perform a genomewide screening for changes in methylation of gene promoter regions associated with the development of the disease.
METHODS
Murine Model of Chronic Tendinopathy in Wild-Type C57/Bl6 Mice Mice for this study were 12 weeks old C57/Bl6 males, bred in-house from a colony established in 2007 using two breeding pairs obtained from Jackson Laboratories. At weaning, males were distributed randomly and maintained with free access to standard chow and water and with constant light cycles (12 h light, 12 h dark). All mice were maintained in the same groups for maturation to 12 weeks and randomly distributed to experimental protocols which were approved by the IACUC of Rush University.
We have previously published on the induction of tendinopathy in murine Achilles tendon by a single injection of TGF-b1 into the body of the tendon, and we noted that the early loss of biomechanical properties and matrix disorganization was largely reversed by extended treadmill running. 10 To generate a model in which structural, biochemical, and cell biological changes become chronic, a more severe injury was generated by two consecutive injections of 100 ng active TGF-b1 (human recombinant, Peprotech, Inc., Rocky Hill, NJ), Two days apart under anesthesia with xylazine (5 ug/g body weight) /ketamine (100 ug/g body weight). This resulted in persistent histopathological changes up to 14 days with cage activity (CA), and worsening of the pathology with treadmill running (TM) to 14 days and 28 days. All injections were between 2pm and 4pm, and treadmill running was between 9am and 11am daily in a designated room as previously described. 10 Mice were euthanized by CO 2 asphyxiation and cervical dislocation between 9am and 10am and tissues collected immediately into RNALater (for RNA isolation) or proteinase K (for DNA isolation).
To control for potential epigenetic effects of anesthesia and needle injuries to the tendon body, we included the following experimental groups: mice (n ¼ 12) were anaesthetized as above on days 0 and 2 and sacrificed on day 3; mice (n ¼ 12) received anesthesia and needle injury (without TGF-b1) on days 0 and day 2. A summary of experimental groups and outcome measures is provided in Table S1 .
Histology
Histological evaluation was done as previously described. 10 Briefly, after formalin fixation and decalcification, specimens were embedded in paraffin and 5 mm thin sections were stained with Hematoxylin and Eosin and images taken at 40Â magnification. Tendinopathy severity scores (0-5) were based on the degree of collagen disorganization observed by a blinded scorer in five 3.5 mm long and 2.0 mm wide longitudinal sections of each tendon. Typical scoring examples are provided in Figure 1 .
Gene Expression Assays
Freshly harvested Achilles tendons were immediately isolated from all surrounding tissue with the peritenon left intact. RNA was isolated as previously described 10 from three separate pools of 12-24 combined Achilles tendons from un-injured (UI) mice and from each experimental and control group (Table S1 ). Briefly, tendon pools in RNALater were flash frozen with liquid N 2 , fragmented by hammer impact at À196˚C in a Bessman Tissue Pulverizer, recovered, and extracted in 1 ml of Trizol by vortexing for 60 s. RNA was purified with an RNeasy MiniKit (Qiagen, Valencia, CA). Consistent with an anabolic response to injury, yields per tendon were: UI $ 305 ng, post-injury 3d $805 ng, postinjury 14d and 14dTM $1800 ng, and post-injury 28d and 28dTM $ 800 ng. A 260 :A 280 for all preparations was >1.90. cDNA was synthesized with 0.5 ug of mRNA (RT 2 First Strand Kit, Qiagen). Chromatin modification enzyme transcript abundances were determined with SYBR qt-PCR array plates (PAMM-085Z, Qiagen) with 84 genes divided into the following functional groups: 6 DNA/Histone Demethylases (DHD), 3 DNA Methyltransferases (DM); 17 Histone Acetyltransferases (HA); 11 Histone Deacetylases (HD), 16 Histone Methyltransferases (HM), 7 Histone Phosphorylation (HP), 9 Histone Ubiquitinases (HU), and 15 SET Domain Proteins with HM activity (SET). The coefficient of variation for triplicate array assays was <3%. The same cDNA preparations were used for Taqman qt-PCR of single genes (Table S2) , with primers from Thermo-Lifetech and the coefficient of variation was <7%.
Changes in transcript abundance (DCt ¼ Ct for transcript of interest minus Ct for the housekeeping gene B2m) were used to calculate the fold change (2^-DDCt) from UI levels for each experimental group. A 1-way ANOVA with Tukey's post-hoc test was conducted using GraphPad Prism 5 (La Jolla, CA) on the DCt values to determine the significance (p < 0.05) in expression of genes in the injured relative to UI groups. Statistical evaluation was not possible on data from single tissue pool controls (anesthesia only, anesthesia with needle injury only, and treadmill only), although it should be recognized that the data obtained with any pool represents the average expression in 12-24 tendons. containing 5 0 -methyl-cytosine instead of cytosine according to Illumina's specified guidelines (www.illumina.com). Adaptorligated fragments of 150-250 bp and 250-350 bp in size were recovered from a 2.5% NuSieve 1:1 agarose gel (Zymoclean TM Gel DNA Recovery Kit, ZR Cat#: D4001). The fragments were then bisulfite-treated using the EZ DNA MethylationLightning TM Kit (ZR, Cat#: D5020). Preparative-scale PCR was performed and the resulting products were purified (DNA Clean & Concentrator TM -ZR, Cat#D4005) for sequencing on an Illumina HiSeq.
Methyl-MiniSeq

TM Sequence Alignments and Data Analysis Sequence reads from bisulfite-treated EpiQuest libraries were identified using standard Illumina base-calling software and then analyzed using a Zymo Research proprietary analysis pipeline, which is written in Python and used Bismark with the murine mm10 reference genome (http:// www.bioinformatics.babraham.ac.uk/projects/bismark/) to perform the alignment. Index files were constructed using the bismark_genome_preparation command and the entire reference genome. The non_directional parameter was DNA METHYLOME IN MURINE TENDINOPATHY applied while running Bismark. All other parameters were set to default. Filled-in nucleotides were trimmed off during methylation calling. The methylation level of each sampled cytosine was estimated as the number of reads reporting a C, divided by the total number of reads reporting a C or T. Fisher's exact test or t-test was performed for each CpG site which has at least five reads coverage, and promoter, gene body (intron and exon), and CpG island annotations were added for each CpG included in the comparison. For post-processing, CpG sites with methylation differentials greater than 80% (0.8) for any experimental group relative to UI were used. Data were further analyzed to identify site specific methylation events across groups and within CpG islands using the UCSC Genome Bioinformatics database (https://genome.ucsc.edu/).
Data Access
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Trella et al., 2016) and are accessible through GEO Series accession number GSE80396
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE80396).
RESULTS
Histological Evaluation
Hematoxylin and Eosin staining was used to evaluate the collagen matrix and cellular responses during cage activity (CA) and treadmill activity (TM), subsequent to the two TGF-b1 injections into the Achilles tendon body ( Fig. 1 ; histopathology denoted by arrows for collagen disorganization [scoring shown in each panel] and asterisk for hypercellularity). The 3d acute response (1 day after second injection) consisted of cell proliferation in the body of the tendon, the peritenon, and the stroma of the adjoining adipose tissue, as well as localized collagen disorganization of the tendon at the injection sites (Fig. 1b) . In mice maintained with CA, hypercellularity, collagen disorganization, and chondroid deposits were still evident at 14 days (Fig. 1c) , but had largely dissipated by 28 days (Fig. 1d) , with small areas of increased cellularity seen in only one of the three mice examined (Fig. 1e) . When TM was applied after the injury, pathology was also evident at 14 days (Fig. 1f) , but had worsened by 28 days, with large areas of collagen disruption extending throughout the tendon body, and chondroid and occasional calcified deposits in between fiber bundles in the area surrounding the TGF-b1 injection sites ( Fig. 1g and h ). Minimal changes in pathology were seen in UI mice with TM for 14 or 28 days ( Fig. 1i and j) .
Expression of Chromatin-Modifying Enzymes
The intra-tendinous injections of TGF-b1 resulted in marked alterations in transcript abundance of genes involved in epigenetic modifications. Baseline expression levels of chromatin modification enzymes in UI mice can be seen in Table S3 . In the 3d acute group (Table 1) , 34 genes covering both histone and DNA modification enzymes showed significant (p < 0.05) increases in expression and three histone-modifying enzymes (Kat2b, Hdac11, and Smyd1) showed a significant decrease. When mice were maintained with CA, the altered transcript levels were reversed to UI levels by 14d with the exception of Aurkb which remained 3.70-fold activated. At 28d, Aurkb returned to UI levels, however Kdm5c became significantly activated (2.44-fold).
In contrast, when injured mice were exposed to TM (Table 2) , mRNA abundance for six of the genes activated at day 3 (Dnmt3b, Ciita, Aurka, Aurkb, Pak1, and Whsc1) remained elevated at 14dTM, and Pak1 remained elevated at 28dTM. Furthermore, the transcript levels of two genes (Dnmt3a, Setd5) which were not altered by TGF-b1 injection at 3d, were increased at 14dTM. In addition, three genes (Hat1, Setd6, and Setd8) and two genes (Atf2 and Ehmt1) were decreased after 14dTM and 28dTM, respectively (all differences, p < 0.05). Importantly, the expression of chromatin modification enzymes in control groups of UI mice with 14 or 28 days of TM (single pool of 15-17 tendons, no statistical test) showed no marked changes (fold change from UI < 1. Notably, anesthesia alone (3dA) or with needle injury (3dAN) appeared to affect expression levels at 3d (Table S4 ). 3dA alone resulted in decreased expression of epigenetic enzymes (with ten genes reduced >3-fold), whereas 3dAN enhanced expression of Esco2 (10.12-fold), Aurka (8.16-fold), and Aurkb (18.45-fold). Thus, since anesthesia alone appeared to have a broad inhibitory effect, it appears that only the transient high activation of Esco2 (26.51-fold), Aurka (33.57-fold), and Aurkb (61.26-fold) seen at 3d with the standard model (Table 1) , can be partly explained by an effect of needle injury without TGF-b1.
Genome-Wide Alterations in the DNA Methylome
Changes in mRNA transcript abundance for DNA methylases and DNA/Histone demethylases (Tables 1 and 2) indicated that changes in the DNA methylome were likely to occur in this tendinopathy model. Therefore, a genome-wide DNA methylome analysis was conducted on tendons from each of the experimental groups (see Methods and Table S1 ). Following the acute TGF-b1 injury, 1058 individual CpG sites, with an additional 27 in CpG islands (CpG I), showed methylation differentials of >80% (0.8) compared to UI levels. After 14 and 28 days, for both CA and TM, this was reduced to approximately 650 CpG sites with differential methylation (DM) ( Table 3 ). The genomewide and gene promoter region distribution of differentially hypomethylated and hypermethylated sites for each experimental group is given in Table S5 . Most importantly for the present study, 3-5% of the DM sites for each experimental group were within promoter gene regions and a variable proportion of these were in CpG islands (Table 3) . Overall, hypomethylation was the predominant response, accounting for 74% (3d), 58% (14d), 87% (28d), 57% (14dTM), and 75% (28dTM) of all modified promoter CpG sites in these experimental groups.
Genes With Differential Promoter Methylation and Effects on Transcript Abundance
It has been proposed that DM of a CpG site within a promoter is most likely to affect transcription if it is located within a CpG island, or if it is one of multiple DM non-island sites. 23 Table 4 lists the genes for each 9  412  13  99  4  31  14d  9  622  0  347  4  232  5  29  0  26  28d  17  620  0  338  4  230  14  47  9  23  14dTM  19  693  1  357  2  280  15  45  4  26  28dTM  17  609  0  333  2  230  11  37  5  27 All sites exhibited greater than 80% differential methylation compared to the same sites in un-injured tendons. Location of CpG sites (non-coding, intron, exon, and promoter) was determined using the UCSC database refseq gene track.
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experimental group with CpG sites which fulfill these criteria, and their chromosomal location is given in Table S6 . All genes of interest (except Foxr1) were identified in only one experimental group showing that differential hypomethylation of the promoter sites is transitory and therefore apparently specific to the time-course, activity level, and possibly pathology in this model. In addition, all sites (except for Sfi1) were found to be differentially hypomethylated, indicative of increased expression levels of all genes affected. Further, it is perhaps notable that the hypomethylation (>80%) of sites in the acute response at 3 days occurred in both island (four sites in four genes) and non-island (seven sites in three genes) locations, whereas at later times (14dTM, 28d, and 28dTM), essentially all (12 of 13 sites) were in CpG islands, however the possible significance of this difference is not known.
To examine the potential effect of these methylation changes on transcription, the fold-change in transcript levels (relative to UI) was determined for each gene in three tendon pools from the five experimental groups (Table 5 ). These assays indicated that transcription of most of these genes was modulated (primarily increased) to some degree at different stages of the model (for example, 20.9-& 6.1-fold in Peg 12, 4.5-fold in Cnot7, 4.4-& 3.8-fold in Usp9x, 3.9-fold in Leprel2, 3.6-& 3.8-fold in Mmp25 and 3.5-fold in Cend1), however the wide variability in transcript abundance between pools (details in Table S7) means that statistical significance was not achieved. Perhaps, the widely variable expression of these genes (coefficient of variation between three pools is $12%) is indicative of short-term fluctuations in transcript abundance due to mRNA instability or multiple mechanisms of control. This idea is supported by the fact that the coefficient of variation was <7% for the assay of these genes in triplicates from a single RNA pool (data not shown).
Despite this variability, several potentially important associations between promoter methylation status and transcript abundance in the TGF-b1 injury model were evident (Table 5 ). For instance, hypomethylation of the Mmp25 promoter at 14dTM was accompanied by the predicted high transcript abundance, which was higher than at the 3d and 28dTM time-points at which the Mmp25 promoter was normally methylated. Conversely, hypermethylation of the Sfi1 promoter at 14dTM was accompanied by increased transcript abundance, suggesting that promoter methylation was not an important mechanism of control in this instance. This also appears to be the case for Igfbp6, where promoter hypomethylation at 14dTM was not associated with a significant change in transcripts. Hypomethylation at 3d of Cend1, Baiap2l1, Mirlet7c-2, and Rbmxl2 promoters was associated with the expected increase in abundance of transcripts for Cend1 and Baiap2l1, but there was a decreased abundance of Mirlet7c-2 and Rbmlx2 transcripts. Moreover, Cend1 and Baiap2l1 transcripts remained elevated in both 14d and 14dTM groups, despite normalization of the promoter methylation. Such results could be explained by particularly long halflives for these mRNA species. For Leprel2, Hoxc4, and Foxf1 with promoter hypomethylation in the 28d group, the transcript abundance was unaltered relative to the UI group, however, for these genes the late hypomethylation may have resulted in increased transcription at >28d post-injury time-points, which was 
80% HYPO Numbers in parenthesis denote the number of affected sites within that gene promoter. Methylation status (%) represents the differential compared to un-injured mice with the average differential methylation given for multiple sites.
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beyond the scope of the current study. It should also be noted that the increased transcript abundance for Leprel2 in the 3d and 14d groups, where promoter methylation was not changed relative to UI, suggests that expression of this gene (and others in Table 5 ) is controlled by factors other than promoter methylation. Also, for the three genes (Usp9x, Cnot7, and Peg12) showing >80% hypo-methylation at 28dTM, only Peg12 exhibited markedly increased transcript abundance at that time-point. Lastly, Foxr1, Grm4, and Shisa7 transcripts were below the level of detection at all time points, and Gm19557 (gene without any known function) was not assayed.
DISCUSSION
The primary objective of this study was to use a murine Achilles tendinopathy model with acute, intermediate, and chronic phases to investigate whether tissue changes in the model (such as collagen disorganization, chondroid metaplasia, and loss of tensile properties 10 ), which are broadly characteristic of human tendinopathies, are accompanied or preceded by changes in the methylation status of promoter regions of tendon DNA. Secondly, we aimed to determine whether promoter methylation status was predictive of changes in transcript abundance and whether the identity of the transcripts might provide novel insights into tendinopathic changes. In summary, 19 genes displayed differential promoter methylation in a treatment-group specific manner, and notably 18 of these genes involved hypomethylation. Twelve of the identified genes also exhibited marked differences in mRNA transcript abundance between the groups. To investigate whether a putative change in the abundance of one or more of the 19 gene products might impact tendon function we undertook a limited literature search using the murine gene function on PubMed and identified studies relating the gene to multipotent mesenchymal cells, fibroblasts, tendon, and/or extracellular matrix. In this way we identified five genes (Leprel2, Foxf1, Mmp25, Igfbp6, and Peg12) which demonstrate strong relevance. Notably, three of the five exhibit functions closely related to collagen fiber organization.
Firstly, Leprel2 has the potential to profoundly affect collagen matrix organization in the tendon as it has a critically important and tissue-specific role in the unique assembly and packing of tendon collagen type I fibrils. 24, 25 Thus, modulation of Leprel2 expression in the tendon could readily explain the fiber disorganization which is a hallmark of tendon pathologies, including tendinopathy. Secondly, Foxf1 induces integrin b3 expression, with high specificity in mouse embryonic fibroblasts. 26 This finding appears to be important since this integrin was identified through the BORG database of genomic and biomedical knowledge as one of four strong candidate risk genes for human tendinopathy (which included COL11A2, ELN, ITGB3, and LOX). 27 Thirdly, proteomic analysis of pericellular proteins in developing tendons has shown that Mmp25 (like Leprel2 and Foxf1) is likely involved in collagen fibril and matrix assembly. 28 Fourthly, a 29 and also by its sensitivity to hypoxia, 30 which has often been implicated in tendinopathic change. 21 Lastly, the dramatic increase in Peg12 expression in the 14dTM group might be related to its capacity to bind Gsk3 31 and potentially reduce production of inflammatory cytokines in macrophage-type cells in response to tolllike receptors. 32 Furthermore, in this regard it is interesting that analysis of the array data for chromatin-modifying enzymes shows that six of the genes most affected overall (Dnmt3b, Ciita, Aurka, Pak1, Hat1, and Atf2) have been implicated in the control of macrophage polarization in innate inflammation. While the role of inflammation in tendon injury is still heavily debated, 33 recent evidence suggests that early macrophage involvement in ligament wound healing is necessary for maintenance of repair responses including angiogenesis, cell differentiation, and collagen production. 34 It should be noted that there was no clear relationship between methylation status and transcript abundance for many of the genes identified by this study. In this regard, recent reviews 35, 36 have underlined the complexity of the causes and effects of cytosine methylation on downstream transcription, so that the earlier supposition 37 that hypomethylation necessarily results in high transcription (and perhaps vice-versa) is, while possible in a context-dependent fashion, an over-simplification of the multiple possible effects of methylation levels. In addition, changes in transcript levels may partly or entirely result from other methods of regulation (e.g., enhancer methylation, transcription factor binding, and miRNA levels) which could contribute to the complexities of transcript abundance reported here.
In addition, cell populations from surrounding tissue (fat pad, synovial tissue, and peritenon) may be present in the samples at varying levels and potentially contribute to the variability exhibited. Due to the need for tissue pooling for mRNA assays and the limited numbers of mice used for this study (see Methods and  Table S1 ), the n values for biological replicates was often not sufficient for robust statistical analysis. However, the post-hoc analysis presented here follows guidelines recently released by the American Statistical Association 38 for evaluating the biological significance (as opposed to statistical significance) of the type of data shown in this paper. Nonetheless, the illustration of transcript modulation for 15 of the genes identified by differential promoter methylation, make it likely that the activity of the protein products of these genes are involved to some degree in the pathogenesis of tendinopathy. In summary, despite these caveats, we postulate that a study of the molecular genomics of Leprel2, Foxf1, Mmp25, Igfbp6, and Peg12 in animal and human tendon could further delineate the pathogenesis of this multifactorial disease.
In conclusion, we wish to point out that in this report we have presented results based on a very limited mining of the data generated by genome wide methylome studies of this kind. Further ongoing work is aimed at utilizing all aspects of this data set (DM CpG sites throughout the genome) in pathway analysis, GO analysis, and identification of other potential disease associations relevant to tendinopathy. Furthermore, data has been deposited in NCBI's Gene Expression Omnibus (Trella et al., 2016) and are publically accessible through GEO Series accession number GSE80396 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE80396).
